Splenectomy with chemotherapy vs surgery alone as initial treatment for splenic marginal zone lymphoma

Rajko,; Milosević,; Milena,; Todorovic, Vesna; Бела,; Balint,; Miodrag,; Jevtic,; Krstic,; Elizabeta,; Ristanovic,; Nebojsa,; Antonijević, Milan D.; Mirjana,; Pavlović,; Maja,; Perunicic,; Milán,; Petrović,

doi:10.3748/wjg.15.3409

Cited by 3 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In cases of lymphoma, splenectomy can be used to decrease disease burden or to treat cases unresponsive to chemotherapy . As is the case in human primary splenic lymphoma, recent veterinary studies suggest that splenectomy should be considered part of the treatment protocol for splenic lymphoma …”

mentioning

confidence: 99%

“…Using this WHO classification system for canine lymphoma, 2 retrospective case series investigating outcome in canine splenic MZL,suggested this form of canine lymphoma may have of a more indolent course of disease than other forms of lymphoma . MZL is considered an indolent form of lymphoma in humans if confined to the spleen, and splenectomy is therefore thought to result in long‐term remission and in most cases is even curative . Based upon these studies, the predictive value of the WHO classification for canine lymphoma and whether splenectomy alone (without adjunctive chemotherapy) may suffice in cases of canine splenic lymphoma suggests that further investigation into how these classifications may apply to the canine population is indicated.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Outcome and Prognostic Factors for Canine Splenic Lymphoma Treated by Splenectomy (1995–2011)

et al. 2015

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

mentioning

confidence: 99%

Outcome and Prognostic Factors for Canine Splenic Lymphoma Treated by Splenectomy (1995–2011)

et al. 2015

View full text Add to dashboard Cite

show abstract

“…©2012 Pulsus Group Inc. All rights reserved Because SMZL cells are rich in the B-lymphocyte surface antigen CD20, the anti-CD20 antibody drug, rituximab, has shown promise in treating the disease. Although spread to the bone marrow and recurrence is common, the disease is often clinically isolated to the spleen, and patients may remain in remission for a prolonged period with splenectomy alone (3,12). Comparative studies investigating splenectomy versus rituximab have shown complete remission achieved after splenectomy in 90% to 100% of cases, and after rituximab in 54% to 88% (12)(13)(14)(15).…”

Section: Discussionmentioning

confidence: 99%

“…Although spread to the bone marrow and recurrence is common, the disease is often clinically isolated to the spleen, and patients may remain in remission for a prolonged period with splenectomy alone (3,12). Comparative studies investigating splenectomy versus rituximab have shown complete remission achieved after splenectomy in 90% to 100% of cases, and after rituximab in 54% to 88% (12)(13)(14)(15). Chemotherapy is not benign, and a phase II trial combining fludarabine and rituximab to treat marginal zone lymphoma reported a 15% mortality rate secondary to toxicity (15).…”

Section: Discussionmentioning

confidence: 99%

“…Chemotherapy is not benign, and a phase II trial combining fludarabine and rituximab to treat marginal zone lymphoma reported a 15% mortality rate secondary to toxicity (15). Thus, current trends would favour splenectomy followed by rituximab therapy to sustain a complete remission, especially if the tissue is strongly CD20 positive (12). There is limited evidence that patients with hepatitis C and SMZL may go into remission with aggressive treatment of the virus using interferon-alpha and ribavirin (16,17).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Splenic Marginal Zone Lymphoma Masquerading as Cirrhotic Hypersplenism for Seven Years

Carr

2012

Canadian Journal of Gastroenterology

View full text Add to dashboard Cite

S plenic marginal zone lymphoma (also known as splenic marginal zone B-cell lymphoma) is one of a family of indolent B-cell lymphomas that remain incompletely characterized. These lymphomas can be globally classified into mucosa-associated lymphatic tissue (MALT) lymphoma, also known as extranodal marginal zone lymphoma, and the nonmucosa-associated lymphatic tissue (non-MALT) marginal zone lymphomas, of which there are two: nodal marginal zone lymphoma (NMZL) and splenic marginal zone lymphoma (SMZL) (1,2). While MALT lymphoma has been well described at the molecular and clinical levels, NMZLs and SMZLs are poorly characterized at the molecular level, but remain clinically distinct. NMZL presents with disseminated nodal involvement, but SMZL is often isolated to the spleen and presents with massive splenomegaly (2,3). The author has previously reported a 39% incidence of primary splenic lymphoma in patients with idiopathic splenomegaly (3). SMZL is rare, and a high index of suspicion is necessary to make the diagnosis in a timely manner.

show abstract

The effect of surgery on primary splenic lymphoma: A study based on SEER database

Pan¹,

Ren

Wang³

et al. 2021

Cancer Medicine

View full text Add to dashboard Cite

Background: Although primary splenic lymphoma (PSL) is rare, it ranks first among splenic primary malignant cancers, and the incidence of lymphoma of spleen has gradually increased in recent years. However, the efficacy of surgery for PSL has not been clinically verified by large sample data, which has affected the formulation of relevant guidelines.Aim: To assess whether surgery can enhance the prognosis PSL patients. Methods: Extracted the data of patients with PSL from The Surveillance, Epidemiology, and End Results (SEER) database, and divided the patients into surgery and non-surgery group. Kaplan-Meier curves and log-rank tests were used to compare the overall survival (OS) and cancer-specific survival (CSS). The propensity score matching (PSM) was used to match the data, then compared the OS and CSS again. The COX proportional hazard regression model was used for univariate and multivariate analysis. Finally, we performed subgroup analysis in different Ahmann stages. Results: A sum of 2207 patients with PSL were enrolled, of which 1062 (48.1%) patients received surgery, and 1145 (51.9%) patients did not undergo surgery.Overall, patients in the surgery group had better OS and CSS. After the propensity scores matching, surgery was not statistically significant in OS and CSS. In the subgroup analysis, surgery was a protective factor for the OS and CSS in Ahmann I/II. However, surgery was no statistical significance in OS and CSS in Ahmann III. In patients with Ahmann Ⅰ/Ⅱ SMZL, surgery was a protective factor for OS and CSS. In patients with Ahmann Ⅲ SMZL, surgery was also statistically significant of OS and CSS. Conclusions: Surgery can significantly improve the prognosis of patients withAhmann Ⅰ/Ⅱ primary splenic lymphoma, but there was no survival difference in the Ahmann Ⅲ patients with or without surgery. For patients with SMZL, surgery was effective for improving OS and CSS.

show abstract

Splenectomy with chemotherapy vs surgery alone as initial treatment for splenic marginal zone lymphoma

Cited by 3 publications

References 0 publications

Outcome and Prognostic Factors for Canine Splenic Lymphoma Treated by Splenectomy (1995–2011)

Outcome and Prognostic Factors for Canine Splenic Lymphoma Treated by Splenectomy (1995–2011)

Splenic Marginal Zone Lymphoma Masquerading as Cirrhotic Hypersplenism for Seven Years

The effect of surgery on primary splenic lymphoma: A study based on SEER database

Contact Info

Product

Resources

About